# HemoShear Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemoshear-therapeutics

- Industry: Biotechnology
- Headquarters: Charlottesville, US
- Website: www.hemoshear.com
- Total disclosed funding: $43M
- Latest round: Series A (Feb 10, 2021)
- Investors on record: 3

## About

Based in the US, HemoShear Therapeutics, Inc. develops innovative technologies for advancing healthcare solutions, particularly in hematology and vascular health, aiming to improve understanding and treatment of blood flow-related conditions.HemoShear Therapeutics, Inc. specializes in creating advanced solutions for hematology and vascular health. Founded in 2008 in Charlottesville, US, by Brian Wamhoff, the company has engaged in several strategic initiatives over the years. Most recently, it has raised USD 3.5 mn in VENTURE DEBT on November 16, 2023, contributing to its total fundraising of USD 43.1 mn through 8 deals.HemoShear Therapeutics, Inc. specializes in innovative products and services aimed at advancing healthcare solutions, specifically in the realm of hematology and vascular health. The company’s core offerings focus on proprietary technologies designed to improve the understanding and treatment of blood flow-related conditions. These products are engineered for use by healthcare professionals and researchers, facilitating more accurate diagnostics and tailored treatment options for patients suffering from various blood and vascular disorders. The end users include hospitals, research institutions, and specialized clinics across North America and Europe, where these technologies are employed to enhance patient outcomes. By addressing critical issues in the treatment of blood flow and blood-related diseases, HemoShear Therapeutics, Inc. positions itself as a leader in this specialized market, providing essential tools to its clientele.HemoShear Therapeutics, Inc. operates on a revenue model that includes direct sales to healthcare providers and partnerships with research institutions. The company generates income through the sale of its flagship products, which are utilized in clinical settings for diagnostic and therapeutic purposes. Transactions typically involve healthcare organizations purchasing products through a B2B framework, where pricing structures are aligned with the specialized nature of the offerings. Moreover, the company may engage in collaborative agreements with other entities to further enhance its market reach and product development. Revenue is derived from the sale of both their proprietary technologies and potential licensing arrangements, ensuring a diversified income stream while catering to the needs of the healthcare sector.HemoShear Therapeutics, Inc. aims to expand its product lineup by introducing new technologies and solutions focused on hematology and vascular health in the near future. The company is also looking to penetrate new markets, particularly in Europe and Asia, by 2025. The recent VENTURE DEBT funding of USD 3.5 mn will support these initiatives, facilitating the development of new products and enhancing market expansion efforts.

## Funding rounds

- Series A, Feb 10, 2021, $43M — Adage Capital Management, Suvretta Capital Management, Janus Henderson Investors

## Investors

- Adage Capital Management — Series A
- Suvretta Capital Management — Series A
- Janus Henderson Investors — Series A